Los Angeles Capital Management
BHVN

Los Angeles Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Los Angeles Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,250
Closed -$642K – 1323
2022
Q3 		$642K Sell
4,250
-661
-13% -$98K ﹤0.01% 848
2022
Q2 		$716K Sell
4,911
-1,697
-26% -$217K ﹤0.01% 835
2022
Q1 		$784K Buy
6,608
+40
+0.6% +$4.99K ﹤0.01% 861
2021
Q4 		$905K Buy
+6,568
New +$835K ﹤0.01% 759
2021
Q2 		– Sell
-6,750
Closed -$461K – 1757
2021
Q1 		$461K Sell
6,750
-5,655
-46% -$457K ﹤0.01% 1251
2020
Q4 		$1.06M Sell
12,405
-15
-0.1% -$1.27K ﹤0.01% 923
2020
Q3 		$807K Buy
12,420
+1,255
+11% +$82.2K ﹤0.01% 905
2020
Q2 		$816K Buy
11,165
+2,285
+26% +$122K ﹤0.01% 923
2020
Q1 		$302K Hold
8,880
– – ﹤0.01% 1052
2019
Q4 		$483K Buy
8,880
+1,030
+13% +$51K ﹤0.01% 1029
2019
Q3 		$328K Buy
+7,850
New +$332K ﹤0.01% 1104

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Los Angeles Capital Management's BHVN Position: Q4 2022 in Review

Los Angeles Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 4,250 shares — an estimated $642K sold.

Los Angeles Capital Management first reported a position in BHVN in Q3 2019 and held it in 11 quarters. The position peaked at $1.06M in Q4 2020. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Los Angeles Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 4,250 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $642K.
  • Los Angeles Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 11 quarters.
  • Los Angeles Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.06M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Los Angeles Capital Management's 13F filing for Q4 2022, filed 6 Feb 2023.